ArticleNature cancer2021

Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma.

Lisa Haas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.